Solengepras trial reduces Parkinson’s disease off time
Solengepras, a new daily pill developed by Cerevance, has completed a late-stage phase three clinical trial, significantly reducing “off” time and movement symptoms for Parkinson’s disease patients. The non-dopaminergic treatment … Read More